After market close on Wednesday, U.S. pharmaceutical giant Eli Lilly (LLY) confirmed its plan to acquire Ventyx Biosciences (VTYX) for approximately $1.2 billion, further expanding its pipeline in inflammation and immune-related diseases. Under the agreement, Lilly will pay $14 per share in cash for all outstanding shares of Ventyx, representing a 62% premium over Ventyx’s 30-day volume-weighted average stock price.
The transaction is expected to close in the first half of 2026.
Ahead of the official announcement, market rumors drove Ventyx shares up nearly 29% on Tuesday, followed by another surge of almost 40% during Wednesday’s regular trading session. Lilly’s stock also rose 4.1% to $1,108.09 on Wednesday, reflecting investor optimism about the strategic acquisition.
Ventyx focuses on developing treatments for inflammatory diseases, with primary programs targeting autoimmune conditions such as ulcerative colitis and Crohn’s disease. The company is also advancing therapies for cardiovascular, cardiometabolic, and Parkinson’s disease. Its pipeline aims to address chronic inflammation, recognized as a key driver in a wide range of chronic illnesses.
In a written statement, David Skovronsky, president of Lilly Research Laboratories, emphasized, “There is increasing evidence that inflammation is a key driver of many chronic diseases. Ventyx’s pipeline addresses a critical need for better treatment options in chronic inflammation.”
Ventyx CEO Raju Mohan commented, “We believe that Lilly is an ideal strategic partner, with unparalleled resources, a passion for innovative oral drugs, and a commitment to advance novel therapies that fill a vast unmet need for patients suffering from these debilitating diseases.” He noted that chronic inflammation is a major risk factor for neuro-inflammatory, cardiometabolic, and cardiovascular conditions, and the collaboration is expected to deliver breakthrough treatments.
Despite its leading position in the weight-loss and diabetes market driven by GLP-1 drugs, Eli Lilly continues to diversify its therapeutic portfolio. In recent years, Lilly has pursued several acquisitions to expand into oncology, pain management, and other areas. The Ventyx deal marks another step in the company’s strategy to broaden its pipeline.
Industry analysis suggests that large pharma companies frequently turn to acquisitions or licensing deals to bring in mid- to late-stage clinical assets from smaller biotech firms, enriching their pipelines while reducing in-house development costs and timelines. Eli Lilly’s strong financial performance in recent years has provided ample flexibility for such strategic investments. Additionally, the company is actively building an artificial intelligence supercomputer to accelerate drug discovery.
Some observers note that despite robust growth in its core business, Lilly must prepare for long-term risks such as patent expirations, rising competition, and potential pipeline gaps. The acquisition not only strengthens Lilly’s position in inflammation but also demonstrates proactive planning for future challenges. With Lilly’s global resources and commercial infrastructure, Ventyx’s research programs are expected to advance more rapidly toward commercialization.
